Bosutinib in the management of chronic myelogenous leukemia

Bosutinib (SKI-606) is an orally available, once-daily dual Src and Abl kinase inhibitor, approved by the US Food and Drug Administration for the treatment of adults with chronic, accelerated, or blast-phase Philadelphia chromosome-positive chronic myelogenous leukemia who are intolerant of or resis...

Descripción completa

Detalles Bibliográficos
Autores principales: Amsberg, Gunhild Keller-von, Schafhausen, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652479/
https://www.ncbi.nlm.nih.gov/pubmed/23674887
http://dx.doi.org/10.2147/BTT.S30182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652479/
https://www.ncbi.nlm.nih.gov/pubmed/23674887
http://dx.doi.org/10.2147/BTT.S30182

Ejemplares similares